Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
By J. Kirchheiner, K. Nickchen, Michael Bauer, Ma-Li Wong, J. Licinio, I. Roots, J. Brockmöller. Molecular Psychiatry, 2004
758 citations recorded by the source corpus.
Subfields: Cellular and Molecular Neuroscience, Molecular Biology, Pharmacology
View Paper: https://www.semanticscholar.org/paper/09c2a702654fb6d0fe0f00f8bad0276500f32c9b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pharmacology
- M. Eichelbaum
- M. Schwab
- Magnus Ingelman-Sundberg
- Ulrich M. Zanger
- C. Rodríguez‐Antona
- A. Gomez
- S. Sim
- William E. Evans
Citations in the corpus
- Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine (2016, background): “Up to a 10-fold difference in the required dose was observed in order to achieve the same plasma concentration in different individuals [37].”
- Pharmacogenomics and individualized drug therapy. (2006, background): “A meta-analysis of the quantitative contribution of CYP2D6 polymorphism to the interindividual variation in dosage of antidepressants (48) has shown that the metabolism and dosage of imipramine, doxepin, maprotiline, trimipramine, desipramine, nortriptyline, clomipramine, and, partially, paroxetine ”
- Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. (2007, methodology): “This area has been covered relatively recently byKirchheiner et al. (2004a) and dosage recommendations in relationship to CYP2D6 genotypes have been presented (Kirchheiner et al., 2004a; Thuerauf & Lunkenheimer, 2006).”
- Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “The area has been extensively reviewed (Kirchheiner et al., 2004; Bertilsson, 2007; Crisafulli et al., 2011; Stingl et al., 2012).”
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants (2006, background): “CYP2C19 is also involved in the metaboism of some antidepressants, and the CYP2C19 enotype has been shown to influence the pharmacokietics of several tricyclic antidepressants and selective erotonin reuptake inhibitors.(4) There is a marked variation in CYP2C19 activity mong homozygous extensive met”